1 / 42

Acute viral neurological diseases

Acute viral neurological diseases. Dr. Mohammed Arif Associate professor Consultant virologist Head of the virology unit College of medicine & KKUH. Acute viral neurological diseases. Aseptic meningitis Encephalitis Post-infectious encephalomyelitis Paralysis. 1-Aseptic meningitis.

jana
Download Presentation

Acute viral neurological diseases

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Acute viral neurological diseases • Dr. Mohammed Arif • Associate professor • Consultant virologist • Head of the virology unit • College of medicine & KKUH

  2. Acute viral neurological diseases • Aseptic meningitis • Encephalitis • Post-infectious encephalomyelitis • Paralysis

  3. 1-Aseptic meningitis • Case definition A syndrome characterized by acute onset of meningeal symptoms, fever and cerebrospinal fluid pleocytosis, with no laboratory evidence of bacterial or fungal meningitis.

  4. Aseptic meningitis • Inflammation of the meninges that cover the brain and spinal cord. • Meninges: duramatter, arachnoid and piamatter. • It is a disease of children and young adults.

  5. Viral etiology • Enteroviruses (85%). • Arboviruses. • Mumps virus. • Lymphocytic choriomeningitis. • Herpes viruses (HSV-1&2, CMV EBV.HHV-6,7,8)

  6. Symptoms • Severe headache. • Fever. • Stiffness of neck. • Nausea. • Vomiting. • Sore throat. • Myalgia.

  7. Symptoms ( CONT.) • Prognosis: recovery is usual in 5 – 14 days. • Complication : meningoencephalitis.

  8. CSF-picture • Clear. • Colorless. • Pleocytosis (increased lymphocytes). • Increased protein. • Normal glucose. • Negative for bacterial culture.

  9. 2-Acute viral encephalitis • Inflammation of the brain. • Caused by direct viral invasion of the brain. • The virus replicate in the brain, causing destructive lesions in the grey matter.

  10. Viral etiology • HSV-1&2. • Enteroviruses. • Arboviruses. • Rabies virus. • Mumps virus.

  11. Clinical features • The incubation period 3-7 days. • Starts with the symptoms of aseptic meningitis followed by : • Drowsiness. • Mental confusion. • Alteration in the level of consciousness.

  12. Clinical features (cont.) • Lack of coordination. • Seizures. • Coma.

  13. Prognosis • The clinical outcome varies, some are mild with full recovery. • Others are severe with permanent neurological sequalae. • Permanent neurological impairments include memory, speech, vision, and muscle control.

  14. Pathology • HSV-encephalitis is characterized by: • Edema, hemorrhage and necrosis confined primarily to the temporal lobes (bilateral or unilateral). • Vascular destruction with infiltrates of neutrophils and lymphocytes. • Glial proliferation. • Eosinophilic intranuclear inclusion bodies.

  15. Pathology • Rabies encephalitis is characterized by: • Perivascular infiltrate of neutrophils and lymphocytes. • Glial proliferation. • Negri bodies, intracytoplasmic inclusion bodies, most prominent in the hippocampus.

  16. Treatment • For enteroviruses and arboviruses, treatment is supportive. There is no anti-viral drug therapy. • For HSV, the recommended dose of acyclovir is 30 mg/ kg per day, in three divided doses for 14 - 21 days.

  17. Methods of Diagnosis • Detection of the viral genome using PCR. • Isolation of the virus in tissue culture, followed by identification of the isolated virus. • MRI (magnetic resonance imaging) provides high quality picture of the brain, useful in the identification of edema, necrosis and hemorrhage.

  18. Methods of Diagnosis (cont.) • CT-scan (computer assisted tomography), useful of identification of internal bleeding. Edema and necrosis. • EEG (electroencephalography) shows spikes and wave activity. Ewaves activity.

  19. 3-Post-infectious encephalomyelitis • It is uncommon complication of many viruses that do not usually affect the CNS including measles, mumps , rubella and varicella. • Encephalitis develops within 6 – 10 days after symptoms of viral illness appear.

  20. Post- infectious encephalomyelitis • The disease is believed to be an auto-immune phenomenon, in which the immune system is triggered by exposure to foreign antigen which is closely related to host proteins normally expressed in brain tissue.

  21. Pathology • Characterized by wide spread demyelinating lesions in the brain and spinal cord. • Lymphocytic infiltration and perivascular cuffing of adjacent blood vessels.

  22. Clinical features • Similar to acute viral encephalitis. • Fever. • Headache. • Stiffness of neck. • Alteration in the level of consciousness. • Mental confusion. • Seizures and coma.

  23. Prognosis • Not good. • Recovery is not complete. • Survivors are left with permanent neurological sequalae.

  24. Treatment • Supportive therapy, there is no specific viral drug therapy.

  25. Lab. diagnosis • By detection of the viral genome to measles, mumps and rubella. • By detection of IgM-Ab to these viruses.

  26. Chronic viral neurological diseases • Subacute sclerosing pan encephalitis (SSPE). • Progressive multifocal leucoencephalopathy. • Tropical spastic paraparesis (TSP).

  27. SSPE • Caused by a mutant measles virus. • Measles virus usually does not cause brain damage, but the mutant virus can invade the brain causing persistent infection and severe form of encephalitis and death. • It affects only unvaccinated children.

  28. Clinical features • It is a rare, slowly progressive disease of the CNS ending in death. • SSPE develops 6 – 12 years after having a primary measles infection. • It is due to reactivation of persistent measles virus in the brain.

  29. Clinical features • The disease starts with personality changes and memory defects followed by • Myoclonic. • Intellectual impairment. • Impairment of vision and speech. • Seizures. • Ataxia • Coma & death.

  30. Laboratory Diagnosis • Presence of high Ab-titre to measles virus in CSF and serum. • MRI provides high quality picture of the brain. • Electro-encephalogram (ECG), is a test for the electrical activity of the brain, which shows a wave pattern whish is typical of SSPE.

  31. Treatment • No cure for SSPE exist. • A combination of Isoprinosine and alpha interferon injected directly into the brain ventricles appears to be the most effective treatment.

  32. Prevention • Immunization of children against measles virus is the only known prevention of SSPE.

  33. Pathology • SSPE is characterized by atrophy of the cortex, loss of white matter and ventricular enlargement. • Perivascular lymphocytic infiltrate and intense gliosis. • Intranuclear inclusion bodies.

  34. Progressive multifocal leukoencephalopathy • Caused by a polyoma virus known as JC virus. • The virus belongs to the family papovaviridae. • Genus: polyoma virus, • The virus is opportunistic, causing brain disorder only in the immunosuppressive patients. • Infection with JC virus is common, but asymptomatic. • 50 – 60% of adults have Ab to the virus.

  35. Clinical features • It is a slowly progressive disease of the CNSthat is usually fatal. • It is due to reactivation of latent virus in the brain. • The disease is characterized by : Hemiparesis Dementia Impaired vision and speech Dysphagia Lack of coordination & seizures.

  36. Prognosis • Death is very common 1 to 6 months when symptoms starts.

  37. Laboratory diagnosis • Detection of the viral genome using PCR. • MRI.

  38. Pathology • Brain autopsy shows multiple demyelination foci prominent in the hemispheres and cerebellum. • Destruction of the white matter. • Prominent gliosis. • Eosinophilic intranuclear inclusion bodies.

More Related